Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Medtech
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Pharma Consulting & Analytics
      • Pharma Consulting & Analytics
      • Data Feeds and APIs
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
    • Multimedia
    • Blog
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Talent
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Breadcrumb

  1. Home
  2. Vantage
  3. Pharmaceutical Companies
  4. Beigene
Thumbnail
June 06, 2022

Asco 2022 weekend story roundup

Thumbnail
June 05, 2022

Asco 2022 – investors clutch at the Tigit straws

Roche’s SCLC study is an unmitigated disaster, but investors holding out for success in NSCLC are thrown a crumb of comfort.

Article image
Vantage logo
May 11, 2022

Looking beyond Roche’s Tigit bombshell

The failure of Skyscraper-01 calls into question Roche’s vast investment in Tigit blockade, but is there broader significance?

Article image
Vantage logo
May 03, 2022

China-backed US approvals continue to hang in the balance

Article image
Vantage logo
April 26, 2022

How Gal appointment could influence strategy at Novartis

Article image
Vantage logo
April 22, 2022

What next for developers seeking to emulate Zydelig?

Article image
Vantage logo
April 20, 2022

First-quarter biotech risers work hard for the win

Amid a difficult start to the year for the drug development sector, Abbvie, Bayer, Ipsen and Lantheus stand out as stock market gainers.

Article image
Vantage logo
April 19, 2022

Outside big pharma, life remains tough for listed developers

A look at stock performances over the first quarter of 2022 shows the extent to which investors have backed away from high-risk drug development.

Article image
Vantage logo
April 04, 2022

Swift resolution emerges to China's non-compliance

Article image
Vantage logo
March 18, 2022

What now for low-cost PD-(L)1 competition?

The prospects for Chinese competitors, ongoing controversy in cervical cancer and a super-fast approval take centre stage.

Article image
Vantage logo
March 11, 2022

Another strike for biotech: China

Use of an auditor that cannot be inspected by the US regulator takes centre stage as Chinese biotech stocks fall.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

June 16, 2022

Vantage Top 10 Most Read Report

June 15, 2022

Asco 2022 eBook

View more...

Editor's Picks

Vantage logo
June 14, 2022

Roche deal fails to Repare the licensing scene

Vantage logo
June 13, 2022

EHA 2022 – Crispr still looks bloody good

Vantage logo
June 05, 2022

Asco 2022 – Enhertu asks, how low can you go?

Vantage logo
June 09, 2022

Asco 2022 movers – cell therapy wins, but it’s not the whole story

Vantage logo
May 30, 2022

Abbvie to become the biggest of pharmas in 2028

Open modal

Evaluate Logo

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)70-4131-0112

Footer menu

  • Terms and conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2022 Evaluate Ltd.